Article Information
History
- November 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Simeng Lin, MBChB1,2,†,
- Nicholas A Kennedy, PhD1,2,†,
- Aamir Saifuddin, BM.BCh3,4,†,
- Diana Muñoz Sandoval, PhD5,†,
- Catherine J Reynolds, PhD5,
- Rocio Castro Seoane, PhD6,
- Sherine H Kottoor, PhD4,
- Franziska P Pieper, MSc5,
- Kai-Min Lin, PhD5,
- David K. Butler, MSc5,
- Neil Chanchlani, MBChB1,2,
- Rachel Nice, MSc2,7,
- Desmond Chee, MBBS1,2,
- Claire Bewshea, MSc2,
- Malik Janjua, MBBS1,2,
- Timothy J McDonald, PhD7,
- Shaji Sebastian, MD8,9,
- James L Alexander, PhD4,10,
- Laura Constable, MRes4,
- James C Lee, PhD11,12,13,
- Charles D Murray, PhD11,
- Ailsa L Hart, PhD3,
- Peter M Irving, MD14,15,
- Gareth-Rhys Jones16,17,
- Klaartje B Kok, PhD18,19,
- Christopher A Lamb, PhD20,21,
- Charlie W Lees, PhD16,22,
- Daniel M Altmann, PhD6,
- Rosemary J Boyton, PhD5,23,†,
- James R Goodhand, MBBS1,2,†,
- Nick Powell, PhD4,10,†,
- Tariq Ahmad, DPhil1,2,*,†,
- Contributors of the CLARITY IBD study
- 1Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- 2Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, UK
- 3Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK
- 4Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
- 5Department of Infectious Disease, Imperial College London, London, UK
- 6Department of Immunology and Inflammation, Imperial College London, London, United Kingdom
- 7Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
- 8IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK
- 9Hull York Medical School, University of Hull, Hull, UK
- 10Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK
- 11Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, UK
- 12Genetic Mechanisms of Disease Laboratory, The Francis Crick Institute, London, UK
- 13Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
- 14Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
- 15School of Immunology & Microbial Sciences, King’s College London, London, UK
- 16Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK
- 17Centre for Inflammation Research, The Queen’s Medical Research Institute, The University of Edinburgh, Edinburgh, UK
- 18Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK
- 19Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK
- 20Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 21Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- 22Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK
- 23Lung Division, Royal Brompton Hospital and Harefield Hospitals, London, UK
- ↵*Corresponding author Address for correspondence:
Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK, tariq.ahmad1{at}nhs.net
↵† Denotes equal contribution
Posted November 11, 2021.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
